Ketamine Treatment Plans for Chronic Conditions

NCT ID: NCT06038409

Last Updated: 2024-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2029-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ketamine can be administered in multiple ways (IV, IM, SubQ, and Sublingual, among others), and there have been few if any, studies that have compared the impact of Ketamine at home without any thearpy.

The study will identify other treatment modalities used in concurrence with Ketamine. Psychotherapy, music therapy, and acutherapy are some of the most popular. How do these adjunct therapies affect the outcomes of Ketamine treatments?

Secondarily, the study will focus on these significant issues to observe the impact of Ketamine treatments and suicidal ideation. Suicidal ideation is multifaceted and is one reason for prescribing off-label Ketamine. Chronic issues such as depression, pain, and anxiety have been identified as underlying causes and may be improvable with Ketamine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pain Depressive Disorder Anxiety Disorders Chronic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Pain

The use of ketamine in chronic pain

Ketamine

Intervention Type DRUG

The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Depressive Disorders

The use of ketamine in depressive disorders

Ketamine

Intervention Type DRUG

The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Anxiety Disorders

The use of ketamine in anxiety disorders

Ketamine

Intervention Type DRUG

The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Chronic Condtions

The use of ketamine in chronic conditions

Ketamine

Intervention Type DRUG

The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine

The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Must have an identifiable chronic condition.

Exclusion Criteria

Healthy population
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

RIVER Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edward Lesofski, MS

Role: STUDY_DIRECTOR

RIVER Foundation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

RIVER Telehealth

Helena, Montana, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ed Lesofski

Role: CONTACT

406-465-9504

James Taggart, MD

Role: CONTACT

415-713-6654

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ed Lesofski, MS

Role: primary

406-465-9504

James Taggart, MD

Role: backup

Frank Yurasek, PhD

Role: backup

Edward Lesofski, MS

Role: backup

Jeffery Newton

Role: backup

Related Links

Access external resources that provide additional context or updates about the study.

http://research.riverofchange.org

RIVER's research web site

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RIVERFoundation 001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ketamine for Depression: An MRI Study
NCT02544607 COMPLETED PHASE4
Study of Depression-Ketamine-Brain Function
NCT01135758 TERMINATED PHASE2
Repeated Neurocognitive Measurements in Depressed Patients
NCT05991232 NOT_YET_RECRUITING PHASE1/PHASE2
Ketamine for Depression and Suicide Risk
NCT02094898 COMPLETED PHASE2
Ketamine in the Treatment of Depression
NCT01558063 COMPLETED PHASE2